Enhanced EBNA2-dependent activity in EBV-transformed B cells

from patients with multiple sclerosis

Marissa Granitto[1,2,3*], Ellie Kim[2,3,4,5*], Carmy Forney[2,3], Cailing Yin[2,3], Arame A. Diouf[2,3],

Andrew vonHandorf[2,3], Phillip Dexheimer[2,3], Sreeja Parameswaran[2,3], Xiaoting Chen[2,3],

Omer Donmez[2,3], Hope Rowden[2], Casey Swoboda[2,6], Molly Shook[2,3], Katelyn Dunn[2,3],

Hania Kebir[7], Maria Vélez-Colón[7], Kenneth Kaufman[2,8,9,10], Danielle Ho[2], Viktoryia

Laurynenka[2,8,9], Lee E. Edsall[2,3], Veronica Brennan[2,3], Ben E. Gewurz[11,12,13], Bahram

Namjou[2,8], Elizabeth Wilson[10,14], Kristen S. Fisher[15], Aram Zabeti[16], Lucinda P.

Lawson[2,3], Jorge I. Alvarez[7], Leah C. Kottyan[2,3,10**], Matthew T. Weirauch[2,3,6,10,17**]

1. Development, Stem Cells & Regenerative Medicine Graduate Program, University of Cincinnati College of Medicine, Cincinnati, OH, 45229, USA.
2. Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA.
3. Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA.
4. Immunology Graduate Program, University of Cincinnati College of Medicine, Cincinnati, OH, 45229, USA.
5. Medical Scientist Training Program, University of Cincinnati College of Medicine, Cincinnati, OH, 45229, USA.
6. Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA.
7. Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
8. Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA.

9. Research Service, US Department of Veterans Affairs Medical Center, Cincinnati, Ohio, USA.

10. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, 45229, USA.

11. Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

12. Department of Microbiology, Harvard Program in Virology, Harvard Medical School, Boston, MA, 02115, USA.

13. Center for Integrated Solutions to Infectious Diseases, Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA.

14. Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA.

15. Department of Pediatrics, Division of Neurology and Developmental Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA.

16. Waddell Center for Multiple Sclerosis, College of Medicine, University of Cincinnati, Cincinnati, OH 45220, USA.

17. Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA.

*equal contributions

**corresponding authors: Matthew.Weirauch@cchmc.org and Leah.Kottyan@cchmc.org

Abstract:

Background. Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system affecting 2.8 million people worldwide. Both genetic and environmental factors contribute to MS risk, with Epstein-Barr virus (EBV) infection being an important environmental factor. To better clarify the role of EBV in MS, we examined its impact on gene expression, chromatin accessibility, and transcription factor binding in primary B cells and EBV-transformed B cells derived from patients with MS and healthy controls.

Results. RNA-seq and ATAC-seq analyses revealed extensive MS-dependent gene expression and chromatin accessibility differences in EBV-transformed, but not in primary B cells. These changes are largely accounted for by the expression levels of EBNA2, an EBV-encoded transcriptional regulator previously implicated in MS. ChIP-seq analysis revealed that EBNA2 binding with its interacting human partners RBPJ, EBF1, and PU.1 is highly enriched at MS genetic risk loci, with extensive EBNA2 allelic binding and increased enrichment at MS genetic risk loci in MS-derived cells.

Conclusions. Our findings demonstrate that enhanced EBNA2 activity in MS alters human gene expression, chromatin accessibility, and transcription factor binding in an MS-dependent manner. Collectively, this study provides new insights into the molecular mechanisms through which EBV, particularly EBNA2, interacts with host genetic risk to contribute to MS pathogenesis.

Background:

Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system, with approximately 2.8 million individuals affected globally [1]. It is the most common cause of non-traumatic neurological disability in young adults [2]. MS is caused by a complex combination of genetic and environmental risk factor interactions [3]. Genetic factors account for approximately 30% of disease risk, with the unaccounted risk being attributed to environmental factors, including Epstein-Barr virus (EBV) infection [4].

Genome-wide association studies have nominated 233 independent risk loci for MS [4]. HLA-DRB-15*01 is the only MS risk locus with a moderate effect size (odds ratio ~ 3), with all other variants having small effect sizes [5]. Genetic risk variants are strongly enriched within non-coding regions of the genome, including enhancers and promoters [6], suggesting that transcriptional dysregulation is likely key to MS etiology.

The most well-supported environmental factor in the etiology of MS is EBV, a common gammaherpesvirus that infects over 90% of the world's population. However, in patients with MS, the infection rate is consistently higher (over 99%) [7]. In 2022, a longitudinal study solidified this relationship by demonstrating that EBV infection is required for MS pathogenesis. In this retrospective study, EBV infection in early adulthood resulted in a 32-fold increased risk of MS, and serum levels of neurofilament light chain, a biomarker of neuronal damage, increased only after EBV infection [8].

Most cell types driving MS pathophysiology are immune-related (e.g., B and T cells), and the success of anti-CD20 therapies in reducing both the severity of symptoms and relapse rate in MS suggests that B cells likely play important roles [9]. EBV infects

both CD21+ B cells and epithelial cells, and EBV-encoded nuclear antigens and

membrane proteins can evade the host's immune system by controlling the host's cell

cycle and preventing apoptosis. EBV can exploit normal B cell differentiation pathways

and cause infected B cells to transition from activated B cell blasts to latently infected

resting memory B cells that escape the host immune response [10, 11]. Latency III is the

most prevalent viral phase during chronic disease, with the EBV transcriptome facilitating

immune evasion [12].

Epstein-Barr virus nuclear antigens expressed during latency, particularly EBNA1

and EBNA2, are hypothesized to play substantial roles in multiple sclerosis (MS). EBNA1

shows molecular mimicry with several human proteins, including GlialCAM, which is

found in the central nervous system [13]. EBNA2 is a viral nuclear protein that serves as

a transcriptional coactivator [14]. It is thought to contribute to MS pathogenesis through

its myriad interactions with the human genome, illustrated by highly enriched binding

activity and EBNA2-dependent chromatin alterations at many autoimmune disease risk

loci [14]. EBNA2 binds indirectly to human DNA via human-encoded transcription factors

(TFs) such as RBPJ, EBF1, and PU.1 [15-17]. Our previous work has demonstrated that

44 MS-associated genetic loci contain a genetic variant located within an EBNA2-

occupied region of the genome [18]. EBNA2 extensively rewires the human genome,

altering the expression of over 400 human genes and modifying chromatin accessibility

at more than 2,000 genomic regions. Importantly, these regions of the human genome

with EBNA2-dependent chromatin accessibility and chromatin looping are highly enriched

at MS genetic risk loci [19].

In this study, we sought to understand how EBV infection leads to altered gene

expression in B cells of patients with MS. To this end, we obtained primary B cells from

patients with MS along with matched healthy controls (HC). After measuring gene

expression and chromatin accessibility in primary B cells, we uniformly infected cells with

the B95-8 strain of EBV. In the resulting transformed B cell lines, we measured gene

expression, chromatin accessibility, and genomic binding of EBNA2 and its human-

encoded TF interaction partners RBPJ, EBF1, and PU.1. Our results establish that EBV

infection causes extensive, robust MS-dependent changes to human gene expression

and chromatin accessibility. EBNA2 expression levels account for virtually all of these

differences, and EBNA2 binds along with its human TF partners at differentially expressed

genes and differentially accessible chromatin. Building upon past studies, we

demonstrate highly enriched EBNA2 occupancy at MS genetic risk loci in MS patient-

derived cells, with increased enrichment in patients with MS relative to healthy controls.

Altogether, this study establishes molecular mechanisms across the human genome

through which EBV rewires B cells in an MS-dependent manner through EBNA2.

Results:

We recruited individuals representing the largest demographic of patients in the United

States: MS women of European ancestry between the age of 25-74 [2]. Twelve individuals

with clinician-diagnosed MS were recruited along with eleven age-matched healthy

controls. The demographics and clinical phenotypes of each individual are provided in

Additional file 1: Table S1. Peripheral blood mononuclear cells (PBMCs) were obtained

from each subject. CD19+ primary B cells were isolated and EBV-transformed B cell lines

were uniformly generated using standard protocols (see Methods, Additional file 2: Fig.

S1).

Extensive MS-dependent gene expression differences in B cells after EBV

transformation, which can be accounted for by *EBNA2* expression levels

We performed bulk RNA-seq experiments in primary B cells and EBV-transformed B cells

from patients with MS and matched controls (see Methods, Additional file 1: Table S2 and

Table S3). We observed very few transcriptional differences in the primary B cells of

individuals with MS and matched controls (19 total genes) (Fig. 1A). However, in EBV-

transformed B cells, we observed 1,060 differentially expressed genes between MS and

HC (Fig. 1B). Based on the established role of EBNA2 in the genetic etiology of MS [18,

20-24], we tested the hypothesis that *EBNA2* expression levels, a proxy for EBNA2

activity, might account for these differences. Indeed, *EBNA2* expression levels across cell

lines accounted for virtually all MS-dependent differential expression (Fig. 1C). Despite

other EBV genes also being dysregulated in MS, no other EBV gene (e.g., *EBNA1, EBNA-*

LP) could account for as much differential expression as *EBNA2* (Additional file 2: Fig.

S2). Among the altered human genes, EBV-induced molecule 2 (also known as *GPR183*)

is a chemotactic receptor that regulates B cell migration [25]. *GPR183* is upregulated in

MS EBV-transformed B cells, and *GPR183* expression levels can be explained by *EBNA2*

expression levels (Additional file 2: Fig. S3). *ACKR3,* another gene that is important for B

cell chemotaxis, is the most significantly upregulated gene in MS EBV-transformed B

cells, and this can also be accounted for by *EBNA2* expression levels (Additional file 2:

Fig. S3). CD40 is a central immune costimulatory receptor that promotes antigen

Figure 1. *EBNA2* expression accounts for extensive MS-dependent gene expression differences in B cells after EBV transformation. A-C. Comparison of human gene expression levels (RNA-seq) in healthy controls (HC) and patients with multiple sclerosis (MS). Horizontal dashed lines indicate an adjusted p-value significance threshold of 0.05. Vertical dashed lines indicate a fold-change threshold of 1.5. Results are shown for primary B cells (A), EBV- transformed B cells (B), and

EBV- transformed B cells after statistically adjusting for *EBNA2* expression levels (C). D. All significant differentially expressed EBV genes in EBV-transformed B cells from HC and patients with MS. Gene expression (RNA-seq) is shown in transcripts per million (TPM). Each dot represents a cell line derived from one individual. Error bars indicate standard deviation. EBV genes in bold are expressed during latency III. E. The total percent of RNA sequencing reads mapped to the EBV genome in EBV-transformed B cells derived from HC and MS. Vertical dashed lines denote quartiles. F. Western blot for EBNA2 protein in HC and MS cell lines (left) and quantification of EBNA2 protein (right). For full blots of EBNA2 and total protein stains, see Additional file 2: Fig. S4. G. *EBNA2* gene expression levels (RNA-seq) in primary B cells in transcripts per million (TPM). Each dot represents primary B cells isolated from one individual. A B cell line without EBV was used as a negative control. Error bars indicate standard deviation.

presentation and lymphocyte activation, is implicated in MS neuroinflammation, and is

currently being targeted therapeutically to reduce disease activity [26]. While there are no

MS-dependent *CD40* expression differences in primary B cells, after EBV transformation

CD40 expression is increased in cells from people with MS relative to controls, with *CD40*

expression in the EBV-transformed B cells again being accounted for by *EBNA2*

expression levels (Additional file 2: Fig. S3).

Consistent with these results, *EBNA2* is the second most significant differentially

expressed gene of the 84 EBV-encoded genes, with significantly higher levels in people

with MS (p adj = 6.61E-06) (Fig. 1D). Among the seven differentially expressed EBV

genes, five are expressed during latency III, including *EBNA2*. We confirmed that total

EBV gene expression levels are not driving these differences (Fig. 1E). We next

performed western blots for EBNA2 in 5 HC and 5 MS cell lines and found significantly

increased levels of EBNA2 protein in MS cells (Fig. 1F, Additional file 2: Fig. S4). Taken

together, we conclude that *EBNA2* expression levels can account for the vast majority of

MS-dependent gene expression differences in EBV-transformed B cells, independent of

overall EBV gene expression levels.

To rule out the possibility that differential prior exposure to EBV might play a role

in the observed gene expression differences, we examined our cohort for evidence of

prior EBV infection through the detection of EBV-derived RNA or DNA, and through

serological evidence of immune responses to EBV. As expected, based on worldwide

EBV infection rates (~95%), everyone in our cohort had evidence of prior infection by EBV

(Additional file 1: Table S1, Additional file 2: Fig. S5).

We next hypothesized that MS-dependent differences in the abundance of

individual B cells that were initially transformed by EBV could drive the observed

differential expression (Fig. 1B). To test this hypothesis, we performed single cell RNA-

sequencing with B cell receptor (BCR) enrichment in cells obtained from 5 patients with

multiple sclerosis and 5 healthy controls (Additional file 2: Fig. S6). To benchmark our

single cell dataset against prior studies, we assessed the differential expression of the

BCR subunit immunoglobulin heavy chain. Consistent with previous findings in peripheral

B cells [27], *IGHV3-74* is the most upregulated immunoglobulin gene in MS (Additional

file 2: Fig. S6). We then asked if differences in B cell clonality might account for the

observed gene expression differences. Because each B cell's BCR is uniquely

rearranged, we used unique BCR sequences as a method to measure the clonality of

each cell line derived from HC and MS. Based on these analyses, we did not find evidence

of differences in the clonality of cell lines between HC and MS after EBV transformation

(Additional file 2: Fig. S6).

Next, we tested whether genetic risk might account for some of the observed gene

expression differences. To this end, we performed whole genome sequencing to enable

imputation of the strongest genetic risk locus (HLA-DRB1*15:01) and calculation of

polygenic risk scores (PRS). The distribution of HLA-DRB1*15:01 alleles was virtually

identical across HC and MS in our cohort (Additional file 2: Fig. S7), which is consistent

with the effect size and the statistical power requirements to identify the original genetic

association [28]. We next calculated MS PRS for each member of our cohort to measure

the cumulative genetic burden of risk in each person. As expected, PRS was higher on

average in the individuals with MS compared to HC (Additional file 2: Fig. S7).

Furthermore, PRS accounted for 16.4% of differential human gene expression,

emphasizing the role of genetics and environment in the observed differences of MS-

derived EBV-transformed B cells compared to controls (Figure 1).

We next sought to further examine the small number of differences in primary B

cells between patients with MS and controls. These differences could explain the

subsequent large number of transcriptional differences after transformation with EBV (Fig.

1B). EBV can only transform B cells that express CD21. We therefore examined a

published single cell RNA-seq dataset from an independent cohort of 3 HCs and 10

people with MS [29] and found that transitional and naïve B cells express the highest

amount of *CD21* among B cell subsets, as expected (Additional file 2: Fig. S8). We found

no differences in the proportion of B cells within the CD21+ transitional and naïve B cell

compartments between HC and MS (Additional file 2: Fig. S8). We identified ten genes

that are differentially expressed in MS relative to controls within the CD21+

transitional/naïve B cell compartment, including *BACH2, AFF3,* and *BANK1*, which have

all previously been implicated in MS (Additional file 2: Fig. S8; Additional file 1: Table S4)

[30-33]. *FANCC* is upregulated in MS CD19+ primary B cells (Additional file 1: Table S3).

A CRISPR screen demonstrated that *FANCC* expression is essential for EBNA2-

dependent transformation of primary B cells to EBV-transformed cell lines [34]. This gene

also demonstrated increased expression in CD21+ transitional/naïve B cells in the

independent set of HC and patients with MS for which we have single cell RNA-seq data,

which is trending toward significance (5.2-fold increase, p-value = 0.17). Taken together,

these data support a model in which primary B cells from patients with MS have higher

expression of *FANCC*, a gene critical for EBV-dependent immortalization of B cells, along

with several other genes with prior links to MS and B cell biology. Strikingly, while the

primary B cells from patients with MS and controls had equivalent levels of RNA mapped

to the EBV genome (Additional file 2: Fig. S5), primary B cells from patients with MS had

significantly higher expression of EBNA2 compared to controls (Mann-Whitney U test, p

= 0.0018) (Fig. 1G). The identification of enhanced EBNA2 expression in the primary B

cells before transformation for this study suggests a fundamental difference in the B cell

compartment of patients with MS relative to controls, a finding consistent with prior studies

[29, 35, 36].

EBV-transformed B cells from patients with MS have distinct chromatin

accessibility patterns compared to controls

Gene expression differences are often driven by differences in chromatin accessibility.

To identify chromatin accessibility differences between people with MS and healthy

controls, we performed ATAC-seq in primary and EBV-transformed B cells in six HC and

six individuals with MS. The resulting data met our stringent quality control criteria, which

are based on the ENCODE consortium standards [37, 38] (Additional file 1: Table S2).

Consistent with the gene expression analysis, we identified only minimal differences in

chromatin accessibility in the primary B cells of HC compared to MS (Fig. 2A, Additional

file 1: Table S5). Also consistent with the gene expression analysis, transformation with

EBV resulted in large differences between MS and HC, with 1,197 peaks that were

stronger in MS and 287 that were stronger in HC (Fig. 2B, Additional file 1: Table S5).

Accounting for *EBNA2* expression levels again removed the vast majority of these

disease-dependent differences (Fig. 2C).

We next examined the concordance between chromatin accessibility changes and

gene expression changes. To this end, we calculated the statistical significance of the

overlap between differentially expressed genes and differentially accessible chromatin

using our RELI algorithm [18] (see Methods, Additional file 1: Table S6). Importantly,

stronger chromatin accessibility in EBV-transformed B cells from patients with MS

corresponded with higher gene expression in these cells (Fig. 2D, right bar). This

relationship was not observed in any of the other possible pairwise relationships; for

example, we did not observe correspondence between closed chromatin and activated

gene expression (Fig. 2D, other bars). As EBNA2 does not directly bind DNA, we also

calculated the enrichment of the DNA binding motifs of its TF interaction partners RBPJ,

EBF1, and PU.1 (encoded by *SPI1*) in differentially accessible chromatin. The motifs for

all three TFs were significantly enriched in chromatin with enhanced accessibility in MS,

but not in chromatin that is more accessible in HC (Fig. 2E), supporting a model where

increased EBNA2 levels result in increased human gene expression levels through

increased chromatin accessibility at regions bound by EBNA2 with its human TF

interaction partners.

Figure 2. *EBNA2* expression accounts for MS-dependent chromatin accessibility differences in EBV-transformed B cells. A-C. Comparison of chromatin accessibility (ATAC-seq) in healthy controls (HC) and patients with multiple sclerosis (MS). Horizontal dashed lines indicate an adjusted p-value significance threshold of 0.05. Vertical dashed lines indicate a fold-change threshold of 1.5. Results are shown for primary B cells (A), EBV- transformed B cells (B), and EBV- transformed B cells after statistically adjusting for *EBNA2* expression levels (C). D. Overlap of all possible pairs of differentially accessible chromatin (ATAC-seq) and differentially expressed genes with 10 kb padding on either side of the TSS (RNA-seq). Each set of chromatin and differential genes were either up in HC or MS. The statistical enrichment of the overlap (measured by RELI, see Methods) is provided as an adjusted p-value on top of each bar. E. DNA binding motif enrichment of exemplary motifs for EBNA2 TF partners RBPJ, EBF1, and SPI1 (PU.1) in accessible chromatin. Enrichment is calculated as % foreground motifs divided by % background motifs (i.e., the percent of randomly selected genome sequences, matching GC content). Asterisks indicate significant motif enrichment (P < 0.05), as calculated by HOMER.

Binding of EBNA2 and human TF interaction partners in EBV-transformed B cells

Our data reveal extensive MS-dependent chromatin accessibility and gene expression

that can be explained by EBNA2 expression levels. To further understand the role of

EBNA2 and its TF interaction partners in these differences, we used ChIP-seq to measure

the genome-wide binding of EBNA2, RBPJ, EBF1, and SPI1 (PU.1) in five HC and five

MS EBV-transformed B cell lines obtained from cohort members with corresponding gene

expression and chromatin accessibility measurements. The resulting data met our

stringent quality criteria that were derived from the ENCODE consortium [37, 38]

(Additional file 1: Table S2).

We observed thousands of robust ChIP-seq peaks, with an elevated average peak

count in MS compared to controls for all four proteins (Fig. 3A). In cells from patients with

MS, EBNA2 binding significantly overlapped genes with increased expression in MS-

derived EBV transformed B cells (Fig. 3B), binding within 10kb of the TSS for over 25%

of genes with MS-dependent expression (Additional file 1: Table S6). Likewise, the three

EBNA2 TF partners also demonstrated significant overlap with genes whose expression

increased in MS-derived cell lines (Fig. 3B). When accounting for co-occurrence of

EBNA2 and human TF ChIP-seq peaks in cells from the same individual with MS, we

again identify the strongest enrichment of overlap of EBNA2-TF pairs at genes with

increased expression in MS-derived cells (Fig. 3C).

Next, we compared chromatin accessibility changes with the binding of EBNA2

and identified statistically significant overlap in cells derived from patients with MS and

MS enhanced chromatin (Fig. 3D). We also observed strong statistical enrichment for the

co-occupancy of EBNA2 with TF partners RBPJ, EBF1, and SPI1 in MS-derived cells

within MS-enhanced chromatin, but not for chromatin that is more accessible in HC (Fig.

3E).

Figure 3. EBNA2 and TF partners bind near genes upregulated in MS EBV-transformed B cells and MS-enriched open chromatin. A. Total number of ChIP-seq peaks for each experiment. Each dot indicates one EBV-transformed cell line from a healthy control (HC) or person with multiple sclerosis (MS). Error bars indicate standard deviation. B. Overlap of all possible pairs of EBNA2, RBPJ, EBF1, or SPI1 (ChIP-seq) and differentially expressed genes with 10 kb padding on either side of the gene (RNA- seq). A combined set of ChIP-seq peaks found in any of the HC or MS-derived EBV-transformed B cells was used for each protein. Differentially expressed genes were higher in either HC or MS-derived EBV-transformed B cells. The statistical enrichment of the overlap (measured by RELI, see Methods) is provided as an adjusted p-value on the y-axis. Dotted line indicates significance threshold. The

number of overlaps is provided on top of each bar. C. Co-occurring binding of EBNA2 with each human transcription factor (RBPJ, EBF1, or SPI1) was called within each EBV-transformed B cell line derived from HC and individuals with MS, using ChIP-seq peaks from the same cell line. For each EBNA2–TF pair, we then compiled a single, pooled set of co-occurrence sites by taking the union of co-occurring peaks observed in any HC- or MS-derived cell line. These co-occurrence peak sets were tested for enrichment near differentially expressed genes (genes upregulated in HC or upregulated in MS). The heatmap shows the significance of each enrichment test, quantified by RELI, for each EBNA2–TF pair and gene set comparison. D. Overlap of all possible pairs of EBNA2, RBPJ, EBF1, or SPI1 (ChIP-seq) and differentially accessible chromatin (ATAC-seq). A combined set of ChIP-seq peaks found in any of the HC or MS-derived EBV-transformed B cells was used for each protein. Chromatin was significantly more accessible in either HC or MS-derived EBV-transformed B cells. The statistical enrichment of the overlap (measured by RELI, see Methods) is provided as an adjusted p-value on the y-axis. The number of overlaps is provided on top of each bar. E. Co-occurrence of EBNA2 and either RBPJ, EBF1, or SPI1 was identified in each EBV-transformed B cell line in both HC and MS. A combined set of co-occurring peaks found in any of the HC or MS-derived cell lines was used. Each set of peaks (ATAC) was significantly more accessible in either HC or MS. The heatmap depicts the significance of the overlap (as measured by RELI) for each pairwise comparison.

In summary, upon assessing EBNA2 binding in cell lines derived from HC, the

overlap with HC-dependent genes and HC-enhanced chromatin was minimal, with far

less significance relative to MS. These results highlight the fact that many more genes

are increased in MS (790 genes) relative to HC (270 genes) (Fig. 1B) and many more

ATAC-seq peaks are enhanced in MS (1,197) relative to HC (287) (Fig. 2B). Altogether,

these results reveal a model of enhanced EBNA2 activity in MS compared to HC, leading

to alterations in EBNA2 binding, human TF binding, human chromatin accessibility, and

human gene expression.

EBNA2 has increased occupancy at MS genetic risk loci

We next asked whether the enhanced EBNA2 activity in MS-derived cells preferentially

targets known MS genetic risk loci. We previously discovered that EBNA2 occupies 44 of

the 109 independent MS-associated genetic loci tested [18]. With the number of

established independent genetic risk loci more than doubling in the past few years, and

the number of available EBNA2 ChIP-seq datasets likewise increasing [19, 39], we next

sought to determine updated EBNA2 occupancy of the expanded set of risk loci in MS-

derived cells. Using the RELI algorithm [18] and data from the present study, we find that

EBNA2 occupies 33 and 25 MS risk loci in EBV-transformed B cells from patients with

MS and HC, respectively (Fig. 4A, Additional file 1: Table S6). Accordingly, the

enrichment of EBNA2 at MS risk loci is more significant in MS derived cells (adjusted p-

value = 5.81E-14) compared to those from HC (adjusted p-value = 2.63E-09). While most

loci and risk variants were shared between HC and MS, many had EBNA2 occupancy

only in MS-derived (13 loci; 25 risk variants) or HC-derived (5 loci; 9 risk variants) cells

(Fig. 4B).

To further expand the set of EBNA2 human genomic targets, we performed ChIP-

seq in 21 additional cell lines in a wide range of B cell types and contexts (Additional file

1: Table S2). Combining these data with all publicly available EBNA2 genomic binding

data, we created an updated global map of EBNA2 occupancy, which reveals EBNA2

occupancy at 83 of the 204 known MS risk loci (Fig. 4C). Pathway enrichment analysis

reveals that EBNA2 binds at MS risk loci near genes related to pathways involved in key

B cell functions such as antigen presentation, response to cytokine, and cytokine

production (Fig. 4D, Additional file 1: Table S7). While most EBNA2-bound MS risk loci

had a single EBNA2 binding event overlapping an MS variant, a subset of MS risk loci

had multiple variants bound by EBNA2, such as the *CSF2RB* locus (n=16 EBNA2-bound

variants) and *HLA* and others, implicating EBNA2 binding at 204 unique MS variants

within 83 independent MS genetic risk loci (Additional file 1: Table S6) [21].

Figure 4. **EBNA2 occupancy at MS genetic risk loci.** A. EBNA2 occupancy at MS risk loci in HC and MS EBV-transformed B cells. Count of EBNA2 ChIP-seq peaks overlapping one or more MS risk variants within each independent locus from HC (left) or MS (right). Overlap significance (as calculated by RELI, see Methods) is indicated with asterisks (*, p = 2.63E-09; **, p = 5.81E-14). B. Comparison of EBNA2 MS risk locus occupancy in HC- or MS-derived cells. (left) Number of MS genetic risk loci where an EBNA2 ChIP-seq peak overlaps with one or more MS risk variant. (right) Total number of these genetic variants (SNPs) (i.e., the counts include multiple variants within a locus). C. Chromomap depicting EBNA2 occupancy at MS risk loci in EBV-transformed B cells. EBNA2 ChIP-seq peaks were collected from a variety of sources, including this study (see Methods). D. Pathway enrichment (Gene Ontology Biological Process) of genes with TSS within 10kb of MS risk loci bound by EBNA2. E. Number of MS risk variants with EBNA2 occupancy at each independent locus.

Genotype-dependent EBNA2 occupancy at MS risk variants

Our analyses indicate that EBNA2 occupancy is significantly enriched at MS risk variants. We next wanted to investigate allele-dependent EBNA2 binding events at these loci. To this end, we used our MARIO pipeline to systematically identify MS risk allele-dependent binding of EBNA2 [18]. In brief, MARIO identifies heterozygous genetic variants within ChIP-seq peaks with significantly different read counts between the two alleles (see Methods). We combined the EBNA2 ChIP-seq experiments produced in this study with publicly available data and identified allele-dependent EBNA2 binding events at MS risk variants. In total, we identified 38 instances of allele-dependent EBNA2 binding to 18 unique MS risk variants in EBV-transformed B cells (Fig. 5A, Additional file 1: Table S8). Among these nominated risk variants, rs17035378 and rs8072391, which both have stronger EBNA2 binding to the MS risk allele, are eQTLs in EBV-transformed B cells for *PLEK* and *STAT3*, respectively (Fig. 5B). When all MS risk variants that are bound by EBNA2 in a genotype-dependent manner are connected through eQTL analysis, including those from this study and previously published variants, a network of genes emerges containing a significant number of interactions (STRING-db analysis, p = 8.73 e-5, Fig. 5C). From the interaction network, we identify a set of genes involved in innate immune response and a second set with roles in cytokine signaling (Fig. 5C). Together, these analyses reveal a large core set of human genes whose expression is likely altered by allele-dependent EBNA2 binding to MS-associated genetic risk variants, revealing important gene/environment disease mechanisms for potential therapeutic targeting.

Figure 5. **Allelic EBNA2 occupancy at MS risk variants**. A. MS-associated genetic risk variants with allele-dependent EBNA2 binding. Each variant is heterozygous and located within an EBNA2 ChIP-seq peak to identify allele-dependent occupancy. The x-axis indicates the percent of reads that map to the strong allele vs the weak allele. A strong allele is defined as the allele preferred in the majority of experiments for that variant. A single variant had discordant allelic results in one out of seven experiments (indicated in hatches). Variants shown in eQTL plots in panel B are bolded. Identical variants in different datasets are connected with vertical bars. B. Genotype-dependent expression of *STAT3* and *PLEK* at MS risk variants with allelic EBNA2 binding (identified in GTeX). MS risk alleles are indicated in red. C. eQTLs at MS variants with allelic EBNA2 binding were identified in the eQTL catalogue. A network of these eQTLs was produced using STRING.

Discussion:

In this study, we show that the EBV-encoded transcriptional regulator EBNA2 has

increased activity in EBV-transformed B cells derived from patients with MS compared to

controls, and that this heightened activity amplifies MS-relevant transcriptional and

chromatin programs. We observe extensive MS-dependent changes in gene expression

and chromatin accessibility that are largely explained by higher EBNA2 expression in MS-

derived EBV-transformed B cells (Fig. 1). To explain this phenomenon, we systematically

evaluated potential confounders, including B cell clonality, prior EBV exposure, the

proportion of CD21+ B cells, overall EBV gene expression, cumulative genetic burden,

and HLA-DRB1*15:01 status; none accounted for the MS-dependent gene expression as

effectively as *EBNA2* expression levels. Generally, increased EBNA2 expression levels

tend to lead to increases in human gene expression levels, affecting genes involved in

MS-relevant pathways such as *GPR183* (B cell migration and crosstalk with T cells),

ACKR3 (B cell adhesion and migration), and *CD40* (B cell proliferation and survival). Our

MS-derived cells also reveal differential binding of EBNA2, differential chromatin

accessibility, and genotype-dependent binding of EBNA2 at MS risk loci.

Overall, we observed dramatic differences between primary B cells before and

after EBV-transformation. Prior to EBV infection, we observed only 19 human genes with

altered expression between MS and controls, with many involved in B cell activation such

as *FANCC*. In an independent single-cell dataset, *FANCC* was again higher in CD21+

transitional/naïve B cells from patients with MS, and a prior CRISPR screen identified

FANCC as essential for EBV-mediated B cell transformation [34]. Together, these

findings suggest that subtle pre-existing differences in activation programs of CD21+ B

cells may prime MS-derived B cells for enhanced EBV transformation and EBNA2-

dependent reprogramming.

Subsequent to EBV transformation, we observed substantial differences between

patients with MS and matched controls on multiple levels: gene expression levels,

chromatin accessibility, and human TF binding. EBNA2 is the most significant

differentially expressed EBV gene in MS-derived cells (Fig. 1D), EBNA2 protein levels

are higher in MS-derived cells (Fig. 1F), and EBNA2 expression level can account for the

extensive gene expression differences seen in HC and MS cell lines (Fig 1C.). Occupancy

of EBNA2 and its human TF binding partners is highly enriched for human genes with

increased chromatin accessibility and increased expression levels in patients with MS

(Fig. 3B, 3D). Many of these EBNA2 binding events also coincide with MS risk loci (Fig.

4), consistent with prior studies from several groups including our own [18, 19, 21, 39]. In

total, EBNA2 occupies 33 and 25 risk loci in EBV-transformed B cells from patients with

MS and HC, respectively (Fig. 4A). While the majority of loci were shared between HC

and MS, many loci had EBNA2 occupancy only in MS- (13 loci) or HC-derived (5 loci)

cells (Fig. 4B). We also identify allelic EBNA2 occupancy at 18 MS risk variants,

strengthening our current understanding of MS genotype-dependent biolog. Compared

to prior EBNA2 studies that relied on established cell lines, our use of patient-derived

EBV-transformed B cells, coupled with allele-dependent analyses, provides direct

evidence that EBNA2 engages MS risk loci in a disease- and genotype-dependent

manner.

Our study uses the B95-8 laboratory strain of EBV to infect primary B cells derived

from controls and patients with MS, providing a controlled model of latent EBV infection

in human B cells with known genetic background and disease status. Consistent with this

model, a recent study in systemic lupus erythematosus demonstrated that EBV

preferentially infects autoreactive antinuclear B cells and reprograms them into antigen-

presenting cells that activate T peripheral helper cells and propagate pathogenic T and B

cell responses [41]. These data provide direct evidence that rare EBV infection events in

autoreactive B cells can initiate systemic autoimmunity, aligning with our proposed model

for EBV–B cell interactions in MS. They also complement a recent study that used

spontaneous lymphoblastoid cell lines to interrogate endogenous EBV in MS-derived B

cells, revealing EBV lytic gene expression in active disease compared to both controls

and patients with stable disease [35]. Those data, together with prior serologic evidence

of EBV reactivation during active MS [42, 43], highlight dysregulated lytic infection. In

contrast, our work focuses on latent EBV infection under controlled viral and disease

conditions, showing that even in the absence of overt lytic reactivation, heightened

EBNA2 activity can remodel chromatin and gene expression at MS risk loci. Together,

these studies support a model in which impaired control of both latent and lytic EBV

infection in B cells contributes to MS pathogenesis. Importantly, both studies reveal

reduced control of EBV B cell infection as a potential driver of multiple sclerosis.

The goals of this study are to clarify how interactions between genetic variants and

EBNA2 influence MS disease processes, and to define the pathways whose regulation

and cell-fate decisions differ in people with MS compared to those without MS. Even

common viruses like EBV can contribute to rare non-communicable diseases such as

MS. This is likely driven by a combination of host genetics, stochastic events, and

environmental factors. In the case of EBV, only a modest minority of people who are

infected experience symptoms and develop mononucleosis [44]. Likewise, of the ~95%

of people with prior EBV infection, the vast majority will not develop subsequent

autoimmune diseases [45]. While up to 50% of this variation may be due to genetics [4],

stochasticity also likely plays a role in determining when EBV will lead to MS or other

autoimmune diseases. Because only a tiny fraction of B cells are infected with the virus,

and the likelihood of those infected B cells possessing a disease-driving BCR is remote

[46], it is possible that the disease-inducing BCR and EBV never occur within the same

cell to initiate the cascade of EBNA2-induced changes we found. Likewise, environmental

factors like vitamin D level and timing of initial EBV infection will also impact the likelihood

of progressing to an MS disease state. Additional studies such as this one are needed to

explore these triggers further, for EBV and other viruses.

Conclusions

Our findings reveal a key role for the EBV-encoded EBNA2 protein in transcriptional

regulation of MS-derived B cells. Heightened EBNA2 expression in MS-derived cells

compared to healthy controls is accompanied by disease-dependent changes in EBNA2

binding, gene expression, and chromatin accessibility. In total, we observe EBNA2

binding at 204 MS genetic risk variants, encompassing 83 distinct MS genetic risk loci,

including allele-dependent EBNA2 binding events to 18 different MS-associated variants.

Collectively, these results reveal an extensive network of EBNA2-induced MS risk-

dependent gene regulatory alterations, providing robust mechanistic targets for

therapeutic intervention.

Methods:

Ethics statement

This study was approved by the Cincinnati Children's Hospital Institutional Review Board (IRB #2017-0430) in March of 2017. Both participants with Multiple Sclerosis (MS) and Healthy Controls (HC) signed informed consent forms prior to participation.

Patient recruitment

Patients with a diagnosis of MS (n=12) were recruited from the Waddell Center for Multiple Sclerosis at the University of Cincinnati or through a study advertisement sent out to Cincinnati Children's Hospital employees. To reduce heterogeneity, the study inclusion criteria for subjects with MS was restricted to European American women between the ages of 25 and 74, which is representative of the largest MS demographic. Eleven age- and ancestry- matched controls were recruited from a study advertisement sent out to Cincinnati Children's Hospital employees. Additional file 1: Table S1 provides the age, sex, self-reported race, ethnicity, and prior EBV infection status of each subject in this study.

Primary B cell isolation

Immediately after sample collection, peripheral blood mononuclear cells (PBMCs) were isolated from blood samples by Ficoll density gradient centrifugation (mean of 132.3 million +/- 84.9 million cells). CD19+ primary B cells were isolated from PBMCs using a Miltenyi negative selection B cell isolation kit (Miltenyi Biotec 130-091-151).

ELISA assays

ELISA assays were performed to evaluate prior history of EBV infection. ELISAs for anti-

EBNA1 IgG (cat #EI 2793-9601 G) and EBV Capsid Antigen IgG (cat #EI 2791-9601 G)

were performed according to the manufacturer's protocol.

EBV infection of primary B cells

B95-8 EBV was prepared from cell supernatants after culture in 10% FBS-supplemented

RPMI-1640 medium for 2 weeks. Viral suspension was filtered twice with 0.45 µm

Millipore filters. The concentrated viral stocks were stored at −80°C. Primary B cells were

infected with 1 mL viral stock based on infection optimization assays and incubated for 3

h for virus adsorption. After infection, cells were washed and cultured. Within the first

month, we confirmed EBV infection by morphological changes and blasting of the cells.

Cells were collected for experiments after at least five passages.

RNA-seq

Total RNA was extracted using the mirVANA Isolation Kit (Ambion) from 11 primary B

cells and 11 EBV-transformed B cell lines and DNase treated with the NucleoSpin® RNA

Clean-up XS Kit (MACHEREY-NAGEL). RNA libraries were prepared using the

SMARTer® Stranded Total RNA-Seq Kit v2 (Takara Bio USA, Inc.), following the

manufacturer's protocol, and sequenced 2x150 bp on an Illumina NovaSeq 6000 at

Cincinnati Children's Hospital Medical Center (CCHMC) Genomics Sequencing Facility

(RRID:SCR_022630).

RNA-seq data were analyzed using the nf-core/rnaseq pipeline (version 3.11.1) (doi: 10.1038/s41587-020-0439-x). Adapter sequence contents were removed using cutadapt [47] (trimgalore version: 0.6.7) (https://journal.embnet.org/index.php/embnetjournal/article/view/200). RNA-seq reads were aligned to the GRCh38 genome augmented with EBV B95-8 coding sequences (ASM240226v1, GCF_002402265.1) using Spliced Transcripts Alignment to a Reference (STAR, version: 2.7.9a) (https://doi.org/10.1093/bioinformatics/bts635). Ribosomal RNA was removed using the Silva Library (https://www.arb-silva.de/) and SortmeRNA v 4.3.4 (https://bioinfo.lifl.fr/RNA/sortmerna/). All RNA-seq datasets used in this study passed our quality control checks, which were facilitated by FastQC (version: 0.11.9) (http://www.bioinformatics.babraham.ac.uk/projects/fastqc). Specifically, RseqQC [48], Qualimap [49, 50], dupRadar [51], and Preseq (https://github.com/smithlabcode/preseq) were used to assess the quality of the datasets. GENCODE (v. 40) [52] annotations for GRCh38 with EBV coding sequence annotations were used to calculate transcript abundance estimates with Salmon (v.1.10.1) (https://doi.org/10.1038/nmeth.4197). The tximport package (https://doi.org/10.12688/f1000research.7563.2) was used to pre-process quantifications and DESeq2 [53] was used to perform differential gene expression analysis. Differentially expressed genes were defined as those genes with a fold-change difference greater than 1.5 and an FDR of less than 0.05. DESeq2 output was filtered to only include genes with transcript per million (TPM) values greater than one in at least three replicates of MS or HC cell lines. Variables accounting for gene expression levels (e.g., the expression level of the EBNA2 gene) were statistically controlled for using the DESeq2 design formula " ~log(gene TPM) + disease_status".

Whole genome sequencing and variant calling

Whole genome sequencing was performed on all MS- and HC-derived cells used in this study. DNA was isolated using a PureLink Genomic DNA Kit (Thermo Fisher #K182001). Libraries were sequenced on an Illumina NovaSeq to generate 100-base paired-end reads. Whole genome sequenced files were mapped to the hg38 genome and variants were called using the Sarek v3.4.1 pipeline [54, 55]. The Sarek pipeline offers multiple programs for alignment, variant calling, and annotation. These samples were aligned with BWA-mem, variants were called with GATK HaplotypeCaller, and annotated with VEP. In addition, joint variant calling was enabled with the "joint_germline" parameter. To determine prior exposure to EBV, the fraction of reads aligning to the EBV genome was assessed by counting the total number of mapped reads in the duplicate marked CRAM file and comparing to the number of reads mapped to the "chrEBV" contig included as a decoy sequence in the hg38 genome.

Western Blot

Cells were lysed and sonicated, and protein concentration was determined using a BCA protein assay. 10 µg of lysates were loaded in 4-12% NuPAGE Bis-Tris gels, run in MOPS buffer, and transferred to a nitrocellulose membrane using the iBlot machine (Thermo Fisher Scientific). The membranes were blocked for 1 hour in Intercept Blocking Buffer at room temperature and incubated overnight at 4°C in Intercept Blocking Buffer + 0.1% Tween 20 with anti-EBNA2 (MABE8, Sigma-Aldrich) antibody diluted to 1:1000. The next day, the membranes were washed three times for 5 minutes with PBS + 0.1% Tween 20.

The washed membranes were then incubated with rotation for 45 minutes with fluorescent

secondary antibodies (diluted to 1:20,000 in Intercept Blocking Buffer + 0.1% Tween +

0.01% SDS). After three more 5-minute washes in PBS + 0.1 Tween 20, the membranes

were imaged using an Odyssey DLx Imaging System (Licor Bioscience).

<u>HLA-DRB-15*01 imputation and Polygenic Risk Score (PRS) calculation</u>

The tag variant and allele for HLA-DRB-15*01 is rs3135388 and the MS risk allele is "A"

[56-58]. The genotype of rs3135388 was obtained from whole genome sequence data of

each individual. We applied a previously developed and validated PRS (PGS002726) for

multiple sclerosis to individuals recruited to this study [59]. PGS002726 was obtained

from the polygenic risk score catalogue (<u>http://www.pgscatalog.org/</u>). We used the

nextflow pipeline "The Polygenic Score Catalog Calculator (pgsc-calc)" to calculate each

individual's PRS from whole genome sequencing data [60].

<u>scRNA-seq</u>

We performed scRNA-seq experiments using cells derived from 5 patients with multiple

sclerosis and 5 healthy controls, pooled into one batch. Single-cell 5' immune profiling

was performed using the Chromium Next GEM Single Cell 5' Kit v2 (Dual Index,

PN-1000263) together with the Single Cell Human BCR Amplification Kit (PN-1000253)

from 10x Genomics (Pleasanton, California). Approximately 17,000 cells were loaded

onto a Chromium Next GEM Chip K to capture 10,000 cells and processed on a

Chromium X Controller to generate barcoded Gel Beads-in-Emulsion (GEMs). GEM-RT,

Dynabeads MyOne SILANE cleanup, and cDNA amplification were performed according

to the manufacturer's protocol (CG000331 Rev F). Amplified cDNA was used for both

gene expression and BCR V(D)J enrichment and subsequent library construction

following the procedures described in the user guide. Final libraries were sequenced on

an Illumina NovaSeq 6000 S4 flow cell (PE 100 bp) using the following sequencing

parameters: Read 1: 28 cycles; i7 Index: 10 cycles; i5 Index: 10 cycles; Read 2: 90 cycles.

Sequencing was performed to a target depth of ~32,500 read pairs per cell for 5' gene

expression libraries and ~5,000 read pairs per cell for the BCR libraries.

Initial read alignment and quantification of FASTQ files was performed using Cell Ranger

(v 6.1.2) [61]. Analysis was performed using Seurat [62]. Cells with less than 1,000 or

greater than 7,000 unique features were removed from downstream analysis. No features

that were expressed in 3 or fewer cells were included. Data were normalized using the

NormalizeData() command. For clustering and Uniform Manifold Approximation and

Projection (UMAP) visualization, 15 components were used; this number was determined

based on the strength of PCs visualized by elbow plot and PC heatmaps after PCA was

performed. The UMAPs and clusters were generated using the FindNeighbors(),

FindClusters(), and RunUMAP() functions (R implementation). The DotPlot was created

using the DotPlot() function. Input features for the dot plot were generated through the

FindAllMarkers() function provided by Seurat to identify differentially expressed

immunoglobulin heavy chain variable region (IGHV) reads.

We also analyzed publicly available single cell RNA-seq data. The dataset GSE133028

was downloaded from the Gene Expression Omnibus, consisting of 3 healthy control and

10 relapsing-remitting multiple sclerosis scRNA samples. Raw fastq files for each patient

were aligned to the human genome using Cell Ranger (v. 7.0.1) to make a Seurat object.

Cells with greater than 15% mitochondrial genes and cells with less than 500 or greater

than 4,500 unique features were removed from analysis. All individual Seurat objects

were integrated using Harmony [63], and B cells were identified using the gene *MS4A1*

(otherwise known as CD20) and made into a separate Seurat object. 40 components

were used to generate UMAP visualization using the FindNeighbors(), FindClusters(), and

RunUMAP() functions. B cell subtypes were identified by comparing the expression levels

of select genes based on previously published studies [64, 65]. *CD21* expression across

B cell subtypes was analyzed using the VlnPlot() function in Seurat, and the proportion of

CD21+ transitional/naïve B cells were extracted to compare between healthy control and

MS. Differential gene expression analysis between healthy control and MS was

performed using the FindMarkers() command in Seurat (p-value cutoff = 0.05, logFC

cutoff = 0.585).

<u>ATAC-seq</u>

Transposase Tn5 with adapter sequences was used to cut accessible DNA [66]. These

accessible DNA sequences with adapter sequences were isolated, and libraries were

prepared from ~50,000 primary B cells or EBV-transformed B cells using the OMNI ATAC

protocol [67]. The libraries were sequenced 2x150 bp on an Illumina NovaSeq 6000 at

the Cincinnati Children's Hospital Medical Center (CCHMC) Genomics Sequencing

Facility.

ATAC-seq data were processed and aligned to a combined human (hg38) and EBV (B95-

8) genome using the ENCODE ATAC-seq pipeline (V2.0.0) [37, 38, 68] (Doi:

10.5281/zenodo.5598324). Aligned reads were then sorted using samtools (v.1.9) and

duplicate reads were removed using Picard (v. 2.20.7)

(https://broadinstitute.github.io/picard/). Peaks were called within the pipeline using

MACS2 (v. 2.2.4) [69]. ENCODE's exclusion list regions were removed from the final set

of peaks. Differential chromatin accessibility was calculated using DiffBind (v. 3.0.15) [70],

with thresholds of a fold-change greater than 1.5 and adjusted p-value less than 0.05.

Each individual-derived cell line was used as a replicate. Expression levels of EBNA2

were statistically controlled for using the DESeq2 design formula "~log(EBNA2 TPM) +

disease_status".

ChIP-seq

We performed ChIP-seq in EBV-transformed B cells from 5 MS and 5 HC for EBNA2

(Abcam ab90543; Lot GR3185425-6), RBPJ (Cell Signaling Technology 5313; Lot 3),

PU.1 (Cell Signaling Technology 2266; Lot 3), and EBF1 (Santa Cruz sc-137065; Lot

J1122) using standard experimental procedures as previously described [19]. Cells were

incubated in a crosslinking solution (1% formaldehyde, 5 mM 4-(2-hydroxyethyl)-1-

piperazineethanesulfonic acid (HEPES) pH 8.0, 10 mM sodium chloride, 0.1 mM

ethylenediaminetetraacetic acid (EDTA), and 0.05 mM ethylene glycol tetraacetic acid

(EGTA)) in Roswell Park Memorial Institute (RPMI) culture medium with 10% fetal bovine

serum (FBS) and placed on a tube rotator at room temperature for 10 min. To stop

crosslinking, glycine was added to a final concentration of 0.125 M, and the tubes were

rotated at room temperature for 5 min. Cells were washed twice with ice-cold phosphate-

buffered saline (PBS), resuspended in lysis buffer 1 (50 mM HEPES pH 8.0, 140 mM

NaCl, 1 mM EDTA, 10% glycerol, 0.25% Triton X-100, and 0.5% NP-40), and incubated

for 10 min on ice. Nuclei were harvested after centrifugation at 5,000 rpm for 10 min,

resuspended in lysis buffer 2 (10 mM Tris–HCl pH 8.0, 1 mM EDTA, 200 mM NaCl, and

0.5 mM EGTA), and incubated at room temperature for 10 min. Protease and

phosphatase inhibitors (Halt™ Protease and Phosphatase Inhibitor Cocktail (100X),

Thermo Fisher Scientific, Waltham, MA) were included in both lysis buffers. Nuclei were

resuspended in sonication buffer (10 mM Tris [pH 8.0], 1 mM EDTA, and 0.1% sodium

dodecyl sulfate (SDS)). An S220 focused ultrasonicator (COVARIS, Woburn, MA) was

used to shear chromatin (150–500-bp fragments) with 10% duty cycle, 175 peak power,

and 200 bursts per cycle for 7 min. A portion of the sonicated chromatin was run on an

agarose gel to verify fragment sizes. Sheared chromatin was pre-cleared with 10 µL of

Protein A or G Dynabeads (Thermo Fisher Scientific) at 4 °C for 1 h.

Immunoprecipitation of TF-chromatin complexes was performed with an SX-8X IP-STAR

compact automated system (Diagenode). Beads conjugated to antibodies against each

TF were incubated with pre-cleared chromatin at 4 °C for 8 h. The beads were then

washed sequentially with wash buffer 1 (10 mM Tris–HCl [pH 7.5], 150 mM NaCl, 1 mM

EDTA, 0.1% SDS, 0.1% NaDOC, and 1% Triton X-100), wash buffer 2 (10 mM Tris–HCl

[pH 7.6], 400 mM NaCl, 1 mM EDTA, 0.1% SDS, 0.1% NaDOC, and 1% Triton X-100),

wash buffer 3 (10 mM Tris–HCl [pH 8.0], 250 mM LiCl, 1 mM EDTA, 0.5% NaDOC, and

0.5% NP-40), and wash buffer 4 (10 mM Tris–HCl [pH 8.0], 1 mM EDTA, and 0.2% Triton

X-100). Finally, the beads were resuspended in 10 mM Tris–HCl (pH 7.5) and used to

prepare libraries via ChIPmentation.

The ChIP-seq libraries were sequenced as single-end 100-base reads on an Illumina

NovaSeq 6000 at the Cincinnati Children's Hospital Medical Center (CCHMC) Genomics

Sequencing Facility. ChIP-seq data were processed and aligned to a combined human

(hg38) and EBV (B-958) genome using the ENCODE ChIP-seq pipeline (V2.0.0) [37, 38,

68] (Doi: 10.5281/zenodo.5598352). Adapters were trimmed using fastp (v. 0.23.2) [71]

prior to processing through the pipeline. Aligned reads were then sorted using samtools

(v.1.9) and duplicate reads were removed using Picard (v. 2.20.7)

(https://broadinstitute.github.io/picard/). Peaks were called using the pipeline's default

parameters with MACS2 (v. 2.2.4) [69]. ENCODE "exclusion list regions" were removed

from the final peak set. QC results are available in Additional file 1: Table S2.

To identify HC- and MS- specific genomic features for ChIP-seq, all peaks that were found

in each condition were combined and overlapping events were merged using bedtools

[72]. Peaks unique to HC or MS were identified using the bedtools command "subtract -

A". Shared peaks were determined by removing all condition-specific peaks from the total

peak set.

<u>Enrichment analysis for functional genomic datasets</u>

We used the RELI algorithm to estimate the significance of the overlap between the

genomic feature sets (e.g., ChIP-seq peaks) generated in this study [18]. As input, RELI

takes the genomic coordinates of peaks from two datasets. RELI then systematically

intersects these coordinates with one another, and the number of input regions

overlapping the peaks is counted. Next, a p-value describing the significance of this

overlap is estimated using a simulation-based procedure in which the peaks from the first

dataset are randomly distributed within the union coordinates of open chromatin from

human cells. A distribution of expected overlap values is then created from 2,000

iterations of randomly sampling from the negative set, each time choosing a set of

negative examples that match the input set in terms of the total number of genomic loci.

The distribution of the expected overlap values from the randomized data resembles a

normal distribution and can thus be used to generate a Z-score and corresponding p-

value estimating the significance of the observed number of input regions that overlap

each dataset.

<u>GWAS data set curation</u>

We obtained GWAS data from the NHGRI-EBI GWAS catalog [73] and the supplemental

dataset from the International Multiple Sclerosis Genetics Consortium GWAS publication

[4]. A genome-wide significance cutoff of 5×10^{-8} was used to establish the statistical

significance of a variant and its association to a given disease or trait. Independent loci

were identified using LD-based pruning in PLINK [74] (window size 300,000 kb, SNP shift

size 100,000 kb, and $r^2 < 0.2$).

<u>Pathway enrichment analysis</u>

Pathway analysis for MS and HC differentially expressed genes was performed using

Enrichr [75, 76].

<u>TF DNA binding motif enrichment analysis</u>

The HOMER software package (v. 4.9) [77] was used to calculate TF DNA binding site

motif enrichment for a custom library containing the human CisBP database motifs (build

2.0) [78, 79]. HOMER was modified to use a log_2-based likelihood scoring system.

<u>Identification of allele-dependent sequencing reads using MARIO</u>

Allele-dependent behavior was identified in sequencing reads using the MARIO pipeline

[18]. Briefly, the MARIO pipeline identifies allele-dependent behavior by weighing (1) the

imbalance between the number of reads that are mapped to each allele, (2) the total

number of reads mapped at each variant, and (3) the number and consistency of available

replicates. These variables are combined into a single Allelic Reproducibility Score (ARS),

which reflects the degree of allelic behavior observed for the given heterozygous variant

in the given data set. MARIO ARS values exceeding 0.4 were considered to be allelic,

following our previous study [18]. We implemented the MARIO pipeline for EBNA2 ChIP-

seq data from this study along with publicly available EBNA2 binding data [19, 40]. To

select for consistent allele-dependent binding activity, we identified and graphed ChIP-

seq peaks with at least 9 reads on top of an MS variant and with at least 15% difference

between the reads mapping to the strong and weak alleles (Fig. 5A, Additional file 1:

Table S8).

To expand our reach, we assessed additional EBNA2 ChIP-seq experiments performed

in our laboratory, including the cell lines GM12878, IB4, AG876, and Jiyoye. Additionally,

we included MS risk variants with published allelic EBNA2 binding activity (Additional file

1: Table S8) [18, 19]. All identified MS risk variants that were overlapped by EBNA2 ChIP-

seq peaks in an allelic manner were assessed for eQTL function using release 7 of the

eQTL Catalogue [80]. Gene targets of these eQTLs (p-value < 0.01) were used as input

to STRING [81] (Fig. 5C).

Figure Legends

Figure 1. *EBNA2* expression accounts for extensive MS-dependent gene

expression differences in B cells after EBV transformation. A-C. Comparison of

human gene expression levels (RNA-seq) in healthy controls (HC) and patients with

multiple sclerosis (MS). Horizontal dashed lines indicate an adjusted p-value significance

threshold of 0.05. Vertical dashed lines indicate a fold-change threshold of 1.5. Results

are shown for primary B cells (A), EBV- transformed B cells (B), and EBV- transformed B

cells after statistically adjusting for *EBNA2* expression levels (C). D. All significant

differentially expressed EBV genes in EBV-transformed B cells from HC and patients with

MS. Gene expression (RNA-seq) is shown in transcripts per million (TPM). Each dot

represents a cell line derived from one individual. Error bars indicate standard deviation.

EBV genes in bold are expressed during latency III. E. Percent of RNA sequencing reads

that mapped to the EBV genome in EBV-transformed B cells derived from HC and MS.

Vertical dashed lines denote quartiles. F. Western blot for EBNA2 protein in HC and MS

cell lines (left) and quantification of EBNA2 protein levels (right). For full blots of EBNA2

and total protein stains, see Additional file 2: Fig. S4. G. *EBNA2* gene expression levels

(RNA-seq) in primary B cells in transcripts per million (TPM). Each dot represents primary

B cells isolated from one individual. A B cell line without EBV was used as a negative

control. Error bars indicate standard deviation.

Figure 2. *EBNA2* expression accounts for MS-dependent chromatin accessibility

differences in EBV-transformed B cells. A-C. Comparison of chromatin accessibility

(ATAC-seq) in healthy controls (HC) and patients with multiple sclerosis (MS). Horizontal

dashed lines indicate an adjusted p-value significance threshold of 0.05. Vertical dashed

lines indicate a fold-change threshold of 1.5. Results are shown for primary B cells (A),

EBV- transformed B cells (B), and EBV- transformed B cells after statistically adjusting

for *EBNA2* expression levels (C). D. Overlap of all possible pairs of differentially

accessible chromatin (ATAC-seq) and differentially expressed genes with 10 kb padding

on either side of the TSS (RNA-seq). Each set of chromatin and differential genes were

either higher in HC or in MS. The statistical enrichment of the overlap (measured by RELI,

see Methods) is indicated as an adjusted p-value above each bar. E. DNA binding motif

enrichment of exemplary motifs for EBNA2 TF partners RBPJ, EBF1, and SPI1 (PU.1)

within accessible chromatin. Enrichment is calculated as % foreground motif occurrence

divided by % background motif occurrence (i.e., the percent of random sequences,

matching GC content). Horizontal dashed lines indicate significant motif enrichment

($P < 0.05$), as calculated by HOMER.

Figure 3. EBNA2 and TF partners bind near genes upregulated in MS EBV-transformed B cells and MS-enriched open chromatin. A. Total number of ChIP-seq peaks for each experiment. Each dot indicates one EBV-transformed cell line from a healthy control (HC) or person with multiple sclerosis (MS). Error bars indicate standard deviation. B. Overlap of all possible pairs of EBNA2, RBPJ, EBF1, or SPI1 (ChIP-seq) and differentially expressed genes with 10 kb padding on either side of the gene (RNA-seq). A combined set of ChIP-seq peaks found in any of the HC or MS-derived EBV-transformed B cells was used for each protein. Differentially expressed genes were higher in either HC or MS-derived EBV-transformed B cells. The statistical enrichment of the overlap (measured by RELI, see Methods) is indicated as an adjusted p-value on the y-axis. Dotted line indicates significance threshold. The number of overlaps is provided above each bar. C. Binding co-occurrence of EBNA2 with each human TF (RBPJ, EBF1, or SPI1) was calculated within each EBV-transformed B cell line derived from HC and individuals with MS, using ChIP-seq peaks obtained from the same cell line (i.e., the same individual). For each EBNA2–TF pair, a single, pooled set of co-occurrence sites was compiled by taking the union of co-occurring peaks observed in any HC- or MS-derived cell line. These co-occurrence peak sets were tested for enrichment near differentially expressed genes (genes upregulated in HC or upregulated in MS). The heatmap indicates the significance of each enrichment test, quantified by RELI, for each EBNA2–TF pair and gene set comparison. D. Overlap of all possible pairs of EBNA2, RBPJ, EBF1, or SPI1 (ChIP-seq) and differentially accessible chromatin (ATAC-seq). A combined set of ChIP-seq peaks found in any of the HC or MS-derived EBV-transformed B cells was used for each protein. "Enhanced chromatin" was significantly more accessible in either

HC or MS-derived EBV-transformed B cells. The statistical enrichment of the overlap

(measured by RELI, see Methods) is indicated as an adjusted p-value on the y-axis. The

number of overlaps is provided above each bar. E. Co-occurrence of EBNA2 and either

RBPJ, EBF1, or SPI1 was calculated in each EBV-transformed B cell line in both HC and

MS. A combined set of co-occurring peaks found in any of the HC or MS-derived cell lines

was used. Each set of peaks (ATAC-seq) was significantly more accessible in either HC

or MS. The heatmap depicts the significance of the overlap (as measured by RELI) for

each pairwise comparison.

Figure 4. **EBNA2 occupancy at MS genetic risk loci.** A. EBNA2 occupancy at MS risk

loci in HC and MS EBV-transformed B cells. Count of EBNA2 ChIP-seq peaks

overlapping one or more MS risk variants within each independent locus from HC (left) or

MS (right). Overlap significance (as calculated by RELI, see Methods) is indicated with

asterisks (*, p = 2.63E-09; **, p = 5.81E-14). B. Comparison of EBNA2 MS risk locus

occupancy in HC- or MS-derived cells. (left) Number of MS genetic risk loci where an

EBNA2 ChIP-seq peak overlaps with one or more MS risk variant. (right) Total number of

these genetic variants (i.e., the counts can include multiple variants within a single locus).

C. Chromomap depicting EBNA2 occupancy at MS risk loci in EBV-transformed B cells.

EBNA2 ChIP-seq peaks were collected from a variety of sources, including this study

(see Methods). D. Pathway enrichment (Gene Ontology Biological Process) of genes with

TSS within 10kb of MS risk loci bound by EBNA2. E. Number of MS risk variants with

EBNA2 occupancy at each independent locus.

Figure 5. **Allelic EBNA2 occupancy at MS risk variants**. A. MS-associated genetic risk

variants with allele-dependent EBNA2 binding. Each variant is heterozygous and located

within an EBNA2 ChIP-seq peak (which enables allele-dependent calculations). The x-

axis indicates the percent of reads that map to the strong allele vs the weak allele. A

strong allele is defined as the allele preferred in the majority of experiments for that

variant. A single variant had discordant allelic results in one out of seven experiments

(indicated in light hatch marks). Variants shown in eQTL plots in panel B are shown in

bold. Identical variants in different datasets are connected with vertical bars. B. Genotype-

dependent expression of *STAT3* and *PLEK* at MS risk variants with allelic EBNA2 binding

(identified in GTeX). MS risk alleles are indicated in red. C. eQTLs at MS variants with

allelic EBNA2 binding were identified in the eQTL catalogue. A network of these eQTLs

was produced using STRING.

<u>Supplemental Figures and Tables</u>

Additional file 1. Supplementary tables.

Table S1. Patient demographic information and clinical phenotypes. This contains the

demographics and clinical phenotypes of each individual (Healthy Controls and patients

with Multiple Sclerosis).

Table S2. Functional genomics data quality assessments. This contains the data quality

summary report for all ChIP, ATAC, and RNA-seq datasets used.

Table S3. RNA-seq raw and analyzed data. This contains the TPM and differential

analysis for RNA-seq data.

Table S4. Single cell RNA-seq differential analysis of CD21+ Naïve and Transitional B

cells. This contains differential expression analysis of the public single cell RNA-seq

dataset GSE133028, particularly in the CD21+ Naïve and Transitional B cell

compartment.

Table S5. ATAC-seq differential analysis. This contains the differential analysis for ATAC-

seq data.

Table S6. Integrated analysis of genomic datasets using RELI. This contains enrichment

analyses performed using RELI including all MS risk variants and unique loci that are

overlapped by EBNA2.

Table S7. Pathway analysis of genes proximal to EBNA2-bound MS risk loci. This

contains the pathway analysis (Enrichr) for the genes proximal to EBNA2-bound MS risk

loci.

Table S8. Analysis of EBNA2-bound alleles using MARIO. This contains allelic EBNA2

binding events derived from our patient cohort, previously published EBNA2 ChIP-seq

datasets, and published EBNA2 binding events from previous studies [18, 19].

Additional file 2. Supplementary figures.

Figure S1. EBV-transformed B cell line generation.

Figure S2. EBNA2 expression level accounts for the largest amount of differentially

expressed genes compared to other EBV genes.

Figure S3. EBNA2-dependent changes in gene expression.

Figure S4. Increased EBNA2 protein in MS-derived EBV-transformed B cells.

Figure S5. Evidence of prior exposure of individuals in this study to EBV.

Figure S6. Single cell RNA-sequencing with BCR enrichment allows for enumeration of

unique clones for each EBV-transformed B cell line.

Figure S7. Multiple sclerosis genetic risk variants do not fully account for differential gene

expression in EBV-transformed B cells derived from HC and MS.

Figure S8. There are few transcriptional differences in CD21+ transitional/naïve B cells

between HC and MS.

References

1. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I, et al: **Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.** *Mult Scler* 2020, **26:**1816-1821.

2. Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA: **Multiple sclerosis.** *Nat Rev Dis Primers* 2018, **4:**43.

3. Olsson T, Barcellos LF, Alfredsson L: **Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis.** *Nat Rev Neurol* 2017, **13:**25-36.

4. International Multiple Sclerosis Genetics C: **Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility.** *Science* 2019, **365**.

5. Hollenbach JA, Oksenberg JR: **The immunogenetics of multiple sclerosis: A comprehensive review.** *J Autoimmun* 2015, **64:**13-25.

6. Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, Reynolds AP, Sandstrom R, Qu H, Brody J, et al: **Systematic localization of common disease-associated variation in regulatory DNA.** *Science* 2012, **337:**1190-1195.

7. DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, Ascherio A: **Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up.** *Arch Neurol* 2006, **63:**839-844.

8. Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, Elledge SJ, Niebuhr DW, Scher AI, Munger KL, Ascherio A: **Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.** *Science* 2022, **375:**296-301.

9. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, et al: **Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.** *N Engl J Med* 2017, **376:**221-234.

10. Zhao B, Zou J, Wang H, Johannsen E, Peng CW, Quackenbush J, Mar JC, Morton CC, Freedman ML, Blacklow SC, et al: **Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth.** *Proc Natl Acad Sci U S A* 2011, **108:**14902-14907.

11. Thorley-Lawson DA: **EBV Persistence--Introducing the Virus.** *Curr Top Microbiol Immunol* 2015, **390:**151-209.

12. Ressing ME, van Gent M, Gram AM, Hooykaas MJ, Piersma SJ, Wiertz EJ: **Immune Evasion by Epstein-Barr Virus.** *Curr Top Microbiol Immunol* 2015, **391:**355-381.

13. Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, Fernandes RA, Gomez AM, Nadj GS, Bartley CM, et al: **Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM.** *Nature* 2022, **603:**321-327.

14. Cable JM, Grabowski JC, Luftig MA: **EBNA2 and EBNA-LP: The Earliest Viral Latency Proteins.** *Curr Top Microbiol Immunol* 2025.

15. Waltzer L, Logeat F, Brou C, Israel A, Sergeant A, Manet E: **The human J kappa recombination signal sequence binding protein (RBP-J kappa) targets the Epstein-Barr virus EBNA2 protein to its DNA responsive elements.** *EMBO J* 1994, **13:**5633-5638.

16. Johannsen E, Koh E, Mosialos G, Tong X, Kieff E, Grossman SR: **Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1.** *J Virol* 1995, **69:**253-262.

17. Murata T, Noda C, Narita Y, Watanabe T, Yoshida M, Ashio K, Sato Y, Goshima F, Kanda T, Yoshiyama H, et al: **Induction of Epstein-Barr Virus Oncoprotein LMP1 by Transcription Factors AP-2 and Early B Cell Factor.** *J Virol* 2016, **90:**3873-3889.

18. Harley JB, Chen X, Pujato M, Miller D, Maddox A, Forney C, Magnusen AF, Lynch A, Chetal K, Yukawa M, et al: **Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity.** *Nat Genet* 2018, **50:**699-707.

19. Hong T, Parameswaran S, Donmez OA, Miller D, Forney C, Lape M, Saint Just Ribeiro
M, Liang J, Edsall LE, Magnusen AF, et al: **Epstein-Barr virus nuclear antigen 2**
extensively rewires the human chromatin landscape at autoimmune risk loci.
Genome Res 2021, **31:**2185-2198.
20. Mechelli R, Manzari C, Policano C, Annese A, Picardi E, Umeton R, Fornasiero A,
D'Erchia AM, Buscarinu MC, Agliardi C, et al: **Epstein-Barr virus genetic variants are**
associated with multiple sclerosis. *Neurology* 2015, **84:**1362-1368.
21. Ricigliano VA, Handel AE, Sandve GK, Annibali V, Ristori G, Mechelli R, Cader MZ,
Salvetti M: **EBNA2 binds to genomic intervals associated with multiple sclerosis and**
overlaps with vitamin D receptor occupancy. *PLoS One* 2015, **10:**e0119605.
22. Afrasiabi A, Parnell GP, Fewings N, Schibeci SD, Basuki MA, Chandramohan R, Zhou Y,
Taylor B, Brown DA, Swaminathan S, et al: **Evidence from genome wide association**
studies implicates reduced control of Epstein-Barr virus infection in multiple
sclerosis susceptibility. *Genome Med* 2019, **11:**26.
23. Afrasiabi A, Parnell GP, Swaminathan S, Stewart GJ, Booth DR: **The interaction of**
Multiple Sclerosis risk loci with Epstein-Barr virus phenotypes implicates the virus
in pathogenesis. *Sci Rep* 2020, **10:**193.
24. Keane JT, Afrasiabi A, Schibeci SD, Swaminathan S, Parnell GP, Booth DR: **The**
interaction of Epstein-Barr virus encoded transcription factor EBNA2 with multiple
sclerosis risk loci is dependent on the risk genotype. *EBioMedicine* 2021, **71:**103572.
25. Gatto D, Brink R: **B cell localization: regulation by EBI2 and its oxysterol ligand.**
Trends Immunol 2013, **34:**336-341.
26. Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, Dufek M,
Saubadu S, Bejuit R, Truffinet P, et al: **Inhibition of CD40L with Frexalimab in Multiple**
Sclerosis. *N Engl J Med* 2024, **390:**589-600.
27. von Budingen HC, Kuo TC, Sirota M, van Belle CJ, Apeltsin L, Glanville J, Cree BA,
Gourraud PA, Schwartzburg A, Huerta G, et al: **B cell exchange across the blood-brain**
barrier in multiple sclerosis. *J Clin Invest* 2012, **122:**4533-4543.
28. Schmidt H, Williamson D, Ashley-Koch A: **HLA-DR15 haplotype and multiple sclerosis:**
a HuGE review. *Am J Epidemiol* 2007, **165:**1097-1109.
29. Ramesh A, Schubert RD, Greenfield AL, Dandekar R, Loudermilk R, Sabatino JJ, Jr.,
Koelzer MT, Tran EB, Koshal K, Kim K, et al: **A pathogenic and clonally expanded B**
cell transcriptome in active multiple sclerosis. *Proc Natl Acad Sci U S A* 2020,
117:22932-22943.
30. Bae SC, Lee YH: **Association between BANK1 polymorphisms and susceptibility to**
autoimmune diseases: A meta-analysis. *Cell Mol Biol (Noisy-le-grand)* 2017, **63:**29-35.
31. International Multiple Sclerosis Genetics C, Wellcome Trust Case Control C, Sawcer S,
Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, et
al: **Genetic risk and a primary role for cell-mediated immune mechanisms in multiple**
sclerosis. *Nature* 2011, **476:**214-219.
32. Itoh-Nakadai A, Hikota R, Muto A, Kometani K, Watanabe-Matsui M, Sato Y, Kobayashi
M, Nakamura A, Miura Y, Yano Y, et al: **The transcription repressors Bach2 and Bach1**
promote B cell development by repressing the myeloid program. *Nat Immunol* 2014,
15:1171-1180.
33. Tsukumo SI, Subramani PG, Seija N, Tabata M, Maekawa Y, Mori Y, Ishifune C, Itoh Y,
Ota M, Fujio K, et al: **AFF3, a susceptibility factor for autoimmune diseases, is a**
molecular facilitator of immunoglobulin class switch recombination. *Sci Adv* 2022,
8:eabq0008.
34. Ma Y, Walsh MJ, Bernhardt K, Ashbaugh CW, Trudeau SJ, Ashbaugh IY, Jiang S, Jiang
C, Zhao B, Root DE, et al: **CRISPR/Cas9 Screens Reveal Epstein-Barr Virus-**

Transformed B Cell Host Dependency Factors. *Cell Host Microbe* 2017, **21:**580-591 e587.

35. Soldan SS, Su C, Monaco MC, Yoon L, Kannan T, Zankharia U, Patel RJ, Dheekollu J, Vladimirova O, Dowling JW, et al: **Multiple sclerosis patient-derived spontaneous B cells have distinct EBV and host gene expression profiles in active disease.** *Nat Microbiol* 2024, **9:**1540-1554.

36. Sarkkinen J, Yohannes DA, Kreivi N, Durnsteiner P, Elsakova A, Huuhtanen J, Nowlan K, Kurdo G, Linden R, Saarela M, et al: **Altered immune landscape of cervical lymph nodes reveals Epstein-Barr virus signature in multiple sclerosis.** *Sci Immunol* 2025, **10:**eadl3604.

37. Hitz BC, Jin-Wook L, Jolanki O, Kagda MS, Graham K, Sud P, Gabdank I, Strattan JS, Sloan CA, Dreszer T, et al: **The ENCODE Uniform Analysis Pipelines.** *bioRxiv* 2023.

38. Luo Y, Hitz BC, Gabdank I, Hilton JA, Kagda MS, Lam B, Myers Z, Sud P, Jou J, Lin K, et al: **New developments on the Encyclopedia of DNA Elements (ENCODE) data portal.** *Nucleic Acids Res* 2020, **48:**D882-D889.

39. Viel K, Parameswaran S, Donmez OA, Forney CR, Hass MR, Yin C, Jones SH, Prosser HK, Diouf AA, Gittens OE, et al: **Shared and distinct interactions of type 1 and type 2 Epstein-Barr Nuclear Antigen 2 with the human genome.** *BMC Genomics* 2024, **25:**273.

40. McClellan MJ, Wood CD, Ojeniyi O, Cooper TJ, Kanhere A, Arvey A, Webb HM, Palermo RD, Harth-Hertle ML, Kempkes B, et al: **Modulation of enhancer looping and differential gene targeting by Epstein-Barr virus transcription factors directs cellular reprogramming.** *PLoS Pathog* 2013, **9:**e1003636.

41. Younis S, Moutusy SI, Rasouli S, Jahanbani S, Pandit M, Wu X, Acharya S, Sharpe O, Wijeratne TU, Harris ML, et al: **Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus.** *Sci Transl Med* 2025, **17:**eady0210.

42. Farrell RA, Antony D, Wall GR, Clark DA, Fisniku L, Swanton J, Khaleeli Z, Schmierer K, Miller DH, Giovannoni G: **Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.** *Neurology* 2009, **73:**32-38.

43. Wandinger K, Jabs W, Siekhaus A, Bubel S, Trillenberg P, Wagner H, Wessel K, Kirchner H, Hennig H: **Association between clinical disease activity and Epstein-Barr virus reactivation in MS.** *Neurology* 2000, **55:**178-184.

44. Crawford DH, Macsween KF, Higgins CD, Thomas R, McAulay K, Williams H, Harrison N, Reid S, Conacher M, Douglas J, Swerdlow AJ: **A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis.** *Clin Infect Dis* 2006, **43:**276-282.

45. Ascherio A, Munger KL: **EBV and Autoimmunity.** *Curr Top Microbiol Immunol* 2015, **390:**365-385.

46. SoRelle ED, Dai J, Reinoso-Vizcaino NM, Barry AP, Chan C, Luftig MA: **Time-resolved transcriptomes reveal diverse B cell fate trajectories in the early response to Epstein-Barr virus infection.** *Cell Rep* 2022, **40:**111286.

47. Martin M: **Cutadapt removes adapter sequences from high-throughput sequencing reads.** *2011* 2011, **17:**3.

48. Wang L, Wang S, Li W: **RSeQC: quality control of RNA-seq experiments.** *Bioinformatics* 2012, **28:**2184-2185.

49. Garcia-Alcalde F, Okonechnikov K, Carbonell J, Cruz LM, Gotz S, Tarazona S, Dopazo J, Meyer TF, Conesa A: **Qualimap: evaluating next-generation sequencing alignment data.** *Bioinformatics* 2012, **28:**2678-2679.

1020   50.   Okonechnikov K, Conesa A, Garcia-Alcalde F: **Qualimap 2: advanced multi-sample**
1021   **quality control for high-throughput sequencing data.** *Bioinformatics* 2016, **32:**292-
1022   294.
1023   51.   Sayols S, Scherzinger D, Klein H: **dupRadar: a Bioconductor package for the**
1024   **assessment of PCR artifacts in RNA-Seq data.** *BMC Bioinformatics* 2016, **17:**428.
1025   52.   Frankish A, Diekhans M, Ferreira AM, Johnson R, Jungreis I, Loveland J, Mudge JM, Sisu
1026   C, Wright J, Armstrong J, et al: **GENCODE reference annotation for the human and**
1027   **mouse genomes.** *Nucleic Acids Res* 2019, **47:**D766-D773.
1028   53.   Love MI, Huber W, Anders S: **Moderated estimation of fold change and dispersion for**
1029   **RNA-seq data with DESeq2.** *Genome Biol* 2014, **15:**550.
1030   54.   Hanssen F, Garcia MU, Folkersen L, Pedersen AS, Lescai F, Jodoin S, Miller E, Seybold
1031   M, Wacker O, Smith N, et al: **Scalable and efficient DNA sequencing analysis on**
1032   **different compute infrastructures aiding variant discovery.** *NAR Genom Bioinform*
1033   2024, **6:**lqae031.
1034   55.   Garcia M, Juhos S, Larsson M, Olason PI, Martin M, Eisfeldt J, DiLorenzo S, Sandgren J,
1035   Diaz De Stahl T, Ewels P, et al: **Sarek: A portable workflow for whole-genome**
1036   **sequencing analysis of germline and somatic variants.** *F1000Res* 2020, **9:**63.
1037   56.   Alcina A, Abad-Grau Mdel M, Fedetz M, Izquierdo G, Lucas M, Fernandez O, Ndagire D,
1038   Catala-Rabasa A, Ruiz A, Gayan J, et al: **Multiple sclerosis risk variant HLA-**
1039   **DRB1*1501 associates with high expression of DRB1 gene in different human**
1040   **populations.** *PLoS One* 2012, **7:**e29819.
1041   57.   Goris A, Walton A, Ban M, Dubois B, Compston A, Sawcer S: **A Taqman assay for high-**
1042   **throughput genotyping of the multiple sclerosis-associated HLA-DRB1*1501 allele.**
1043   *Tissue Antigens* 2008, **72:**401-403.
1044   58.   Zivkovic M, Stankovic A, Dincic E, Popovic M, Popovic S, Raicevic R, Alavantic D: **The**
1045   **tag SNP for HLA-DRB1*1501, rs3135388, is significantly associated with multiple**
1046   **sclerosis susceptibility: cost-effective high-throughput detection by real-time PCR.**
1047   *Clin Chim Acta* 2009, **406:**27-30.
1048   59.   Shams H, Shao X, Santaniello A, Kirkish G, Harroud A, Ma Q, Isobe N, University of
1049   California San Francisco MSET, Schaefer CA, McCauley JL, et al: **Polygenic risk score**
1050   **association with multiple sclerosis susceptibility and phenotype in Europeans.**
1051   *Brain* 2023, **146:**645-656.
1052   60.   Lambert SA, Wingfield B, Gibson JT, Gil L, Ramachandran S, Yvon F, Saverimuttu S,
1053   Tinsley E, Lewis E, Ritchie SC, et al: **Enhancing the Polygenic Score Catalog with**
1054   **tools for score calculation and ancestry normalization.** *Nat Genet* 2024, **56:**1989-
1055   1994.
1056   61.   Zheng GX, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, Ziraldo SB, Wheeler TD,
1057   McDermott GP, Zhu J, et al: **Massively parallel digital transcriptional profiling of**
1058   **single cells.** *Nat Commun* 2017, **8:**14049.
1059   62.   Butler A, Hoffman P, Smibert P, Papalexi E, Satija R: **Integrating single-cell**
1060   **transcriptomic data across different conditions, technologies, and species.** *Nat*
1061   *Biotechnol* 2018, **36:**411-420.
1062   63.   Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, Baglaenko Y, Brenner M,
1063   Loh PR, Raychaudhuri S: **Fast, sensitive and accurate integration of single-cell data**
1064   **with Harmony.** *Nat Methods* 2019, **16:**1289-1296.
1065   64.   Dai D, Gu S, Han X, Ding H, Jiang Y, Zhang X, Yao C, Hong S, Zhang J, Shen Y, et al:
1066   **The transcription factor ZEB2 drives the formation of age-associated B cells.**
1067   *Science* 2024, **383:**413-421.
1068   65.   Verstegen NJM, Pollastro S, Unger PA, Marsman C, Elias G, Jorritsma T, Streutker M,
1069   Bassler K, Haendler K, Rispens T, et al: **Single-cell analysis reveals dynamics of**

human B cell differentiation and identifies novel B and antibody-secreting cell intermediates.** *Elife* 2023, **12**.

66. Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ: **Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position.** *Nat Methods* 2013, **10**:1213-1218.

67. Corces MR, Trevino AE, Hamilton EG, Greenside PG, Sinnott-Armstrong NA, Vesuna S, Satpathy AT, Rubin AJ, Montine KS, Wu B, et al: **An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues.** *Nat Methods* 2017, **14**:959-962.

68. Consortium EP: **An integrated encyclopedia of DNA elements in the human genome.** *Nature* 2012, **489**:57-74.

69. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W, Liu XS: **Model-based analysis of ChIP-Seq (MACS).** *Genome Biol* 2008, **9**:R137.

70. Stark R BG: **DiffBind: differential binding analysis of ChIP-Seq peak data.** http://bioconductor.org/packages/release/bioc/vignettes/DiffBind/inst/doc/DiffBind.pdf; 2011.

71. Chen S, Zhou Y, Chen Y, Gu J: **fastp: an ultra-fast all-in-one FASTQ preprocessor.** *Bioinformatics* 2018, **34**:i884-i890.

72. Quinlan AR, Hall IM: **BEDTools: a flexible suite of utilities for comparing genomic features.** *Bioinformatics* 2010, **26**:841-842.

73. Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, McMahon A, Morales J, Mountjoy E, Sollis E, et al: **The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019.** *Nucleic Acids Res* 2019, **47**:D1005-D1012.

74. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC: **PLINK: a tool set for whole-genome association and population-based linkage analyses.** *Am J Hum Genet* 2007, **81**:559-575.

75. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma'ayan A: **Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool.** *BMC Bioinformatics* 2013, **14**:128.

76. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins SL, Jagodnik KM, Lachmann A, et al: **Enrichr: a comprehensive gene set enrichment analysis web server 2016 update.** *Nucleic Acids Res* 2016, **44**:W90-97.

77. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, Glass CK: **Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities.** *Mol Cell* 2010, **38**:576-589.

78. Weirauch MT, Yang A, Albu M, Cote AG, Montenegro-Montero A, Drewe P, Najafabadi HS, Lambert SA, Mann I, Cook K, et al: **Determination and inference of eukaryotic transcription factor sequence specificity.** *Cell* 2014, **158**:1431-1443.

79. Lambert SA, Yang AWH, Sasse A, Cowley G, Albu M, Caddick MX, Morris QD, Weirauch MT, Hughes TR: **Similarity regression predicts evolution of transcription factor sequence specificity.** *Nat Genet* 2019, **51**:981-989.

80. Kerimov N, Hayhurst JD, Peikova K, Manning JR, Walter P, Kolberg L, Samovica M, Sakthivel MP, Kuzmin I, Trevanion SJ, et al: **A compendium of uniformly processed human gene expression and splicing quantitative trait loci.** *Nat Genet* 2021, **53**:1290-1299.

81. Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, Gable AL, Fang T, Doncheva NT, Pyysalo S, et al: **The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest.** *Nucleic Acids Res* 2023, **51**:D638-D646.

Acknowledgements

This research was funded by the National Institutes of Health (NIH) R01 NS099068, P30 AR070549, R01 AR073228, and R01 AI024717 to M.T.W. and L.C.K.; U19 AI070235, R01 DK107502, R01 AI148276, and U01 HG011172 to L.C.K.; R01 HG010730, R01 GM055479, U01 AI130830, U01 AI150748, R01 AI141569, P01 AI150585, and U24 HG013078 to M.T.W.

We thank the Single Cell Genomics Core (RRID:SCR_022653) at the Cincinnati Children's Hospital Medical Center, especially Kelly Rangel, for their assistance with scRNA-seq. We thank the Cincinnati Children's Hospital Medical Center (CCHMC) Genomics Sequencing Facility (RRID:SCR_022630). We thank John Harley for helpful discussions around the role of EBNA2 in autoimmunity.

Author information

Author notes

Marissa Granitto and Ellie Kim contributed equally to this work. Matthew Weirauch and Leah Kottyan co-led this work.

Author contributions

Conceptualization: M.G., L.C.K., M.T.W.; Study design: M.G., L.C.K., M.T.W., C.F.; Participant recruitment: C.F., V.B., K.F., A.Z.; Statistical analysis design: M.G., L.C.K, M.T.W.; Computational analysis: M.G., P.J.D., A.V.H. S.P., E.K., C.O.S., X.C., L.E.E., K.K., K.F., B.G.; Directed experiments: M.G., C.F., L.C.K., M.T.W.; Performed Experiments: M.G., C.F., C.Y., M.S.S., O.D., A.A.D., K.D., V.L., D.H.; Writing: M.G., E.K.,

1145   L.C.K., M.T.W, L.P.L.; Funding: L.C.K., M.T.W. All authors reviewed and approved the

1146   final manuscript.

1147

Ethics declarations

1148   **<u>Ethics declarations</u>**

1149   <u>Ethics approval and consent to participate</u>

1150   All study participants consented to participate in this study.

1151

1152   <u>Consent for publication</u>

1153   Not applicable.

1154

1155   <u>Competing interests</u>

1156   None.